INTRODUCTION
Chronic kidney disease (CKD) is a serious condition associated with increased healthcare expenditures, decreased quality of life, and premature mortality. As reported by the National Health and Nutrition Examination Survey (NHANES) m, CKD affects 11% (19.2 million) of adult (aged 20 years and older) men and women in the United States (1), and its incidence is likely to further increase with increasing longevity and the rising incidence of obesity and type 2 diabetes mellitus (T2DM). NHANES is a continuous data survey of health and nutritiona} status of U .S. adults, and results are analyzed and released periodically by the ~enters for Disease Control. The NHANES noted a 15.9% increase in the prevalence of CKD between 1988 CKD between and 1994 CKD between and between 1999 CKD between and 2004 . C KD is most common· in persons ~60 years of age (39.4% of this population) but also prese~ts in persons aged 40 to 59 and 20 to 39 years (12.6 and 8.5% of these age groups·, respectively) (2) . T2DM is the leading cause of CKD in developed countries (3) and accounts for45% of all cases of kidney failure (4) .
Kidney disease is defined as an abnormality of kidney structure or function with implications for the health of an individual (5) . The National Kidney Foundation (NKF) bas traditionally categorized CKD into 5 stages based upon the glomerular filtration rate (GFR, expressed as ml.Jmin/1.73 m 2 and commonly reported as nlU.min) ( Table 1 ). In 2003, CKD prevalen~ by stage among the U.S. population was estimated at 3.3% (5.9 million) stage 1, 3.0% (5.3 million) stage 2, 4.3% (7 .6 millioq) stage 3, and 0 .2% each for stages 4 and 5 (1). The Kidney Disease Improving Global clear, clinically relevant, and internationally acceptable definition and classification system; (2) develop a consensus for bone biopsy evaluation and classification; and (3) evaluate laboratory and imaging markers for the clinical assessment of patients with CKD. An ideal classincation system for CKD-mineral and bone disorders (CKDMBDs) would allow categorization of patients based on readily available clinical diagnostic -tools and would help guide treatment. The lack of adequate data and the nonlinearity of CKD does not allow for a classification based o.n severity or treatment at this time. The proposed KDIGO framework for/lassifying CKD-MBDs (Table 3) is based on the presence or absence of laboratory abnormalities, bone disease, and calcification of extraskeletal tissue and is meant to be a descriptive clinical model (8) . KDIOO recommends that the term "renal oSte<?dystrophy" be used exclusively to define altered bone morphology identified by bone biopsy/histomorphometry and be subsequently reported as a unified TMV classification system, which is based upon the skeletal parameters of turnover (T), mineralization (M), and volume (V). Thus , the term CKD-MBDs is used to descnoe a broad clinical syndrome that develops as a systemic disorder characterized by a constellation of abnormalities in regulatory hormones and bone mineral, bone turnover and mineralization, and vascular or soft tissue calcification. CKD-MBDs acknowledges the entire spectrum of disease from early hormonal and mineral disturbances to the late stages of CKD and premature mortality. · Because 96% of all CKD cases fall into stages I to 3 and T2DM is common in early CKD, the endocrinologist is uniquely positioned to address and treat both T2DM and mot•n, "' tho '""""""""1-.;,1 A:CI0,1')<'14,t-,. ")<'IC,l"'\ . 
METHODS
Preparation of this review was assisted by a library resource spe.cfalisr to perform a liternture. search using Ovid MEDLINE, Medical Subject Headings (MeSH), and PubMed National Center for Biotechnology Information. We limited our search to the past 20 years and only English-language articles. Literature search cross-reference terms included "chronic kidney disease," or "chronic renal disease," or '!hemodialysis," or "dialysis," or "kidney failure,"·or "renal insufficiency" combined with "bone diseases," "metabolic," "osteodystrophy," "osteoporosis," "osteomalacia," or."bone minerals." Text words were used to search ISI Web of Science for articles and abstracts not identified in the other databases.
The relevant literature was reviewed by the authors \Vith a focus to (1) define disiwbances of n1inerals and honnones in the course of CK.D; (2) identify the variable radiographic and histomorphometric changes of CKDMBDs; (3) review the association among CKD-MBDs, vascular calcification, CVD, and mortality; and (4) clarify issues in CK.D-MDDs therapy.
RESULTS

Bone Mineral and Regulatory
Hormones in CKD-MBDs
Disturbances of bone mineral metabolism and regulatory honnones may occur early in the course of CKD, with perturbations occurring as early as stage 2 CKD and progressing as kidney function worsens (10) . CKD is associated with disrupted regulation of fibroblast growth factor-23 (FGP-23) and the vitamin D pnrnthyroid honnonc (PTH) axis (11,12). Serum FGF-23 levels rise earlier than and are relatively higher than PTH levels as CKD progresses. PGP-23, which is derived· from osteocytes, is a phosphaturic hormone that also ha~ multiple tissue effects that-influence bone metabolism (13) . The rise in PTH occu~s before serum calcium decreases or seru.m phosphate increases significantly, and this eventually leads to secondary hyperparathyroidism {SHPT). As kidney function declines, a corresponding decrease in vitamin D receptors (VDRs) and calcium-sensing receptors (CaSRs) occurs in the parathyroid glands (14) , making them less responsive to the actions of circulating vitamin D and calcium. All of these ev~nts worsen SHPT and its potential effect on bone. Many patients with stage 2 to 4 CKD may go unrecognized because of a reliance only on serum creatiniile to assess renal status and failure to more accurately assess renal function using th~ GFR. The rate of glomeruJar filtration is generally regarded as the best overall index of renal function in health and disease (15) . Nonna] GFR varies according .to age, gender, body size, and race. The measured GFR (mGFR, as clearance. of exogenous filtration markers such as iothalamate) is P.resently the best direct measure of renal function, and the degree of reduction in mGFR correlates with the severity of structural changes in CKD. Serum measurement of cystatin C has recently gained attention as a sensitive, noncreatinine alternative endogenous marker of filtration (16, 17) (10) in response to a loss of functioning proximal r~nal tubules and reduced activity of renal 1-alpha-hydroxylase, leading to parathyroid gland hyperplasia, elevated blood levels of_ PTH, and SHPT. The combination of low calcitriol and elevated PTH in CKD is now recognized as a cause of bone loss (19) (20) (21) and a major contributor to bone disease commonly seen in stage 4 CKD and present in almost all patients with stage 5 CKD (22, 23) . Elevated PTH levels in late CKD have also been viewed as a possible contribu-. tor to early death (24) , although a receI)t meta-analysis did not find a significant correlation between PTH levels and mortality (25) . Rath~r, in 4,127 patients followed for a median of 60 months, elevated phosphate levels were associated with increased coronary events and death in patients with stage 2 to 3 CKD based upon eGFR (Cockcroft-Gault equation) (26) . Increased mortality has been reported with higher serum levels of both phosphate (25) (26) (27) (28) and FGF-23 (29, 30) in patients with CKD. · Clinical and experimental evidenc.e supports the concept that integrated mechanisms are responsible for the development of s.HPT and bone disease in CKD.
Phosphate retention and hyperphosphatemia directly stimulate parathyroid gland function (24) . However, perturbations of phosphate retention in stage 2 to 3. CKD may n.ot be seen by measurement of serum or urine phosphate (10) .; and possible explanations are that compensatory increases in FGF-23 (29) and PTH lead to decreased renal tubular reabsorptiort of phosphate and increased urinary phosphate excretion. During stages 4 to 5 CKD, when hyperphosphatemia develops, phosphorus can affect parathyroid function both by suppressing blood calcium, contributing to hypocalcemia, and by acting directly on the parathyroid glands. Hyperphosphatemia has a direct effect on posttranscriptional increases in PTH synthesis and secretion (31) and can.induce parathyroid hyperplasia independent of low blood levels of calcium or calcitriol. Phosphate retention interferes with the kidney's ability to produce calcitriol, creating a state of vitamin D deficiency and decreased intestinal absorption of calcium. The calcemic response to PTH infusion is also markedly blunted as early as stage 2 CKD. These abnormalities all contribute. to SHPT.
Phosphate homeostasis is primarily regulated by the kidney. Phosphate is filtered by the renal glomerulus and 80% is then reabsorbed, mostly by the proximal nephron's brush border membrane type Ha sodium-phosphate cotransporter (NaP2a). PTH increases urinary phosphate ~xcretion via cyclic adenosine monophosphate-dependent inhibition of NaP2a expression. However, PTH action does not account for all of phosphate homeostasis. Recent studies have sbown that FGF-23 is involved in the pathophysiology of CKD 1 (fl ,12) and plays a major role in various forms of osteomalacia (32) . FGF-23 is a peptide hormone normally secreted by bone osteocytes and osteoblasts in response to hyperphosphatemia. The rise in fGF-23 mirrors renal phosphate retention and appears to precede the development of SHPT. Serum FGF.:.23 levels have been reported to be persistently increased as early as stage 3 CKD (29) . This FGF-23 rise induces a decline in the number of intact nephrons and is associated with reduced expression of Klotho, the coreceptor required for FGF-23 signaling (33) . Patients with CKD have high serum FGF-23 and low Klotho expression in the kidney_ and parathyroid gland$, suggesting that they could serve as biomarkers for progression of disease (29) and response to therapy (34) (35) (36) . As CKD progresses, serum phosphate, PTH. and FGF-23 levels continue to increase, whereas responsiveness to PTH and FGF-23 decrease. Io late-stage CKD, abnormally high serum FGF-23 levels can no longer red1;1ce serum phosphate effectively. Elevated FGF-23 levels are associated with more rapid CKD progression to ESRD (29) , left ventricular hypertrophy (37) , and premature mortality (29, 30) .
Bone Turnover (BTO) and Mineralization in CKD-MBDs 1
The nature ll!ld type of bone disease that develops in CKD-MBDs may vary among patients. Three types of bone disease, as defined by quantitative bone bistomorphometry, may be encountered in patients with CKD: ()) increased BTO and resorption due to SHPT with or without marrow fibrosis (osteitis"fibrosa), (2) decreased bone turnover and formation (termed 'adynamic bone'), and (3) defective bone mineralization (osteomalacia) (38) . Some patients have a mixed pattern (22, 23) . In order to clarify the inte.rpretation of bone biopsy results in the evaluation of renal osteodystrophy, the TMV classification system allows for 3 key histologic descripto~ to be reported in any combination (Table 3) . Histomorphometry can thereby help to provide a clinically relevant description of the underlying skeletal pathology, (Fig. 2 ) and assist in guiding therapy.
Factors that cause postmenopausal, idiopathlc, or age-related bone loss may contribute to the skeletal abnonnalities of CKD . Inadequate calcium or vitamin D intake or absorption, hypogonadism, tobacco smoking, glucocorticoid steroid use, immobilization, and poor nutritional status may by themselves be a cause of bone loss.
Osteoporosis, defined by the National Institutes of Health Consensus Conference on Osteoporosis, is a decrease in the quantity and/or quality of normally mineralized bone that decreases bone strength and increases the risk of skeletal fracture. Osteoporosis may coexist with CKD-MBDs and may also be present years before CKD-MBr.is become evident. In a study of 421 postmenopausal · women with osteoporosis ~d a GFR >50 mLlmiri, 39% had vitamin D deficiency, as defined by 25-hydroxyvitamin D lev-
, and 33% had frank SHPT (serum PTH above normal laboratory values) (39) . In these women , hypovitaminosis D was associated with either an elevated PTH response and increased BTO or a 'blunted' PTH response and low BTO, the latter theorized to possibly be protective against hypovitaminosis D-related bone loss. Lobao et al ( 40) reported on 103 patients with CKD ( creatinine clear~ncc , 10 to _ 78 rullmin) not rece_ lving dialysis and found that 50 (48.5%) had low bone mineral density (BMD) (40) . In this study, bone loss was found to ~e present in patients with both early and late CKD (median creatinine clearance, 29 Mild HPT, hype.rpamhyroidism, and Of, osteltis fibrosil, area,rentlyuseddlstnct categories, but actually representa rqeof abnormalities along a cottlnwmof medium to hWh-810, aid anyVdepencl,wonCKOduration.
MUO, m iKed uremicCKOMBO, isvariablV
defined lnt.-Ntionally. In thecraphexampl~ it isdf!pitted ashlgh-BTO, ncrmafV, with abnormalM.
The TMVclaulicationS)t5tem moreprecila'Vdescribes the r.nge of pilthologlc ll>normalitiB in CKOMBD.
[BTO, bone turno,er; CKD, dronic kl'*'4Pf disease; MBO, matabotic bonedisease.) Moe 33 (19%) had osteitis fibrosa with osteomalacia, an~ 9 (5%) had low BTO 'adynamic bone,' whereas osteomalacia alone (1 patient, 0.6%) and aluminum deposition (2 patients, 1%) were rare. Paired bone biopsies in 62 of these untreated patients showed progression of CKD~MBDs in all patients within 2 years : These findings are in keeping with the hormone, and mine~al features of higher PfH, lower calcitriol, and higher phosphate levels seen in early CKD. Of interest, McCarthy et al ( 43) did not find an association between early CKD and fracture risk in 427 postmenopausal Caucasian women (median age, 68 years) in a prospective, population-based cohort study followed for up to 25 years (median, 14 years) in Rochester;J\,1innesota. Although univariant arialysis fowtd increased fracture risk associated with declining renal funption, multivrujant analysis did not find any _/lssociation after adjusting for age, · body weight, and BMD. Of.note, the baseline creatinine clearance rate for all patients in this srudy was 78.7 ± 26.6 mLJmin and 44.7 ± 12.7 m.L/min for the 20% of subjects in the lowest quintile. Although few researchers have examined the longitudinal change in bone density in relation to BTO in CKD, high BTO from SHPT leads to bone loss (19) due to bone resorption increased out of proportion to bone formation (38).
As kidney ~nction deteriorates to late-stage CKD, patients are at an increased risk of fracture (19) (20) (21) (44) (45) (46) (47) (48) (49) .
SHPT can result in uiarkedly increased BTO and even marrow fibrosis (e.g., activation of precursor mesenchymal cells, which differentiate into fibroblast-like ceJ.ls and form fibrous tissue adjacent to b~ne trabeculae). Osteitis .fibrosa in CKD-MBDs is manifested by severe SHPT, excessive BTO, and marrow fibrosis, often with increased osteoid production and abnonnal osteoid mineralization (Fig. 2) . Coalescence of large, multinucleated osteoclasts and .fibrotic marrow may result in 'brown tumors' (named for the color of these bone lesions due to hemosiderin · deposits) and appear as lytic or lucent 'cysts' via radiography. Increased osteoid production may be due to increased collagen production exceeding mineralization and/or by abnormal mineralization (i.e., osteomalacia). Rapidly deposited, poorly structured, and undennineralized osteoid is often referred to as 'woven bone' and lacks the lamellar pattern and birefringence seen histologically in normal bone. · Vitamin D is important for collagen synthesis and maturation, as well as normal mineralization of osteoid. F actors important in the development of osteomalacia in CKD-MBDs are vitamin D deficiency and/or resistance to calcitriol action. Aluminum deposition_ in bone can also lead to a skeletal mineralization defect in CKD.
Although osteomalacia can be accurately diagnosed only by means of a tetracycline double-labeled iliac crest bone biopsy for hlstomorphometric analysis, hypovitaminosis D is common tn both the general population (50, 51) and in patients with CI9) (9, 10, 19, 39) . The degree of decline in serum levels of 25-hydroxyvitamin D has been found to · be related to biocherp.ica:l markers of CKD-MBDs ( directly with decreases in mGFR and indirectly with increases in PTH, C-telopeptide, and bone alkaline phosphatase [BAP]) (49) . Low calcitriol levels are also directly related to the degree of renal insufficiency (49) , and hypovitaminosis D contributes to bone loss through decreased intestinal cal-. cium absorption (50 ,52) , lowered bone formation (52) , and increased osteoclastogenesis (53, 54) . .
Fortunately, stage 4 to 5 CKD only accounts for 4% of reported CKD cases in the U.S. (1). Almost all patients with stage 5 CKD h ave abnonnal bone histology. Crosssectional stud,ies of bone histology in dialysis patients reveal different prevalences for types of CKD-MBDs (22, 23, 55, 56) . Although high BTO and SHPT is a predominant find~i in patients with stage 5 CKD; there· is also a high prevalence of decreased BTO, or ABD (22, 23, 56) .
The prevalence of ABD has been reported as 30% in patients with stage 4 CKD and between 15 and 60% in patients with stage 5 CKD requiring dialysis. In patients with ESRD requiring hemodialysis, ABD is more common in Caucasians and less common in African Americans (22) . ABD in CKD-MBDs is characterized histologically by low BTO with very little osteoid accumulation and thin osteoid seams (Fig. 2) (57) . Both the rate of collagen synthesis by osteoblasts and the rate of bone matrix mineralization are subnormal. The latter distinguishes ABD from osteomalacia, in which defects in mineralization ·exceed those in bone fonnation and result in a relative osteoid excess and thick osteoid seams. Variability in the prevale~ce of ABD reported among studies may be related to differences in excess calcium loading, aluminum loading, or presenpe of diabetes (57) (58) (59) (60) . Aluminum bone deposition leading to ABD was a. much greater problem in the era of aluminum-containing phosphate binders and unrecognized aluminum contamination in parenterally administered solutions (especially nutrition and albumin). In theory, ABD is presumed to involve impaired ability to repair skeletal microfractures due to decreased BTO and thereby result in an increased risk of fracture. However, the dinical significance of ABO remains to be detennined. Barreto et al ( 45) identified differences in bone histology with or .... , with011tosteoporosis in 98 patients with ESRD treated with hemodialysis. In that study, the majority (56%) of patients had ABD, with 25% having significant aluminum bone deposition. Osteoporosis was associated with age, female gender, duration of amenorrhea, Caucasian ethnicity, and the serum osteoprotegerin to serum receptor-activator of nuclear factor-KB ligand (RANKL) ratio. Neither hlstologic ABD findings nor serum level.s of PTH, calcium, phosp:iate, or 25-hydroxyvitamin D were predictive of osteoporosis, although there was a trend for calcitriol use to be associated with the absence of osteoporosis (P = .06).
The mechanisms underlying ABD are· not fully knowo., and it may be seen in late CKD either before . or after initiating dialysis. It has been generally believed and accepted that elevated PTH levels (2 to 3 times nonnal} are necessary to maintain normal rates of bone formation in.
patie11ts with stage 4 to 5 CKD and thereby prevent ABD from developing (9, 23, (59) (60) (61) (62) (63) . Patients with ABD have lower PTH levels than those with other CKD-MBDs (22) , and although oversuppression of parathyroid gland activity from cxccs8ivc calcium (62) and/or calcitriol or cillacalcet administration may play a significant role, a similar 'blunting' of PTH with low BTO has been reported in postmenopausal women without CKD (39) . To better understand the dynamic changes in CKD-MBDs following parathyroidectomy (PTX), paired bone biopsies taken before and after surgery were studied by Yajima et al (64) in 18 patients with SHPT and stage 5 CKD requiring hemodialysis. PTH levels, markers ofBTO, bone osteoclast surfaces, and marrow fibrosis all decreased markedly 2 to 4 weeks after PTX. Signifi.cant decreases in the levels of phosphate (from 5.3 ± 1.2 mg/dL to 2.9 ± 1.6 mg/dL) and -PTH (from 1 :1,56.7 ± 448.2 pg/mL to 30.3 ± 61.~ pg/mL) were observed 2 to 4 weeks after PTX, and PTH fell below 30 pg/mL in all but 2 patients. A substantial increase in osteoid volume and tetracyc!:ine !a~el \ 1 las observed compared \Vit.'1 bone biopsies iz~ both low-PTH and high-PTH stage 5 hemodialysis control groups not hav~g PTX, suggesting that increased mineralization was taking place. Tetracycline label in PTX subjects was observed not only at the mineralization front of trabecular surlaces but also around the osteocyte lacunar walls and canaliculi within the basic multicellular units (BMUs}. The authors reported an increase in the number of empty lacunae., a reduction in lacunar volume, and a significant decline in the number of osteocytes after PTX. Whether or. not these acute BMU changes after PTX were in part due to the high doses of calcium and/or vitamin D (1-alphahydroxyvitamin D 3 as oral alfacalcidol) administered and whether or not these bone features persist long-term after PTX is unknown. It is important to recognize the nonnal physiology of c.alcium flux into and out of bone, because there is a common misconception that bone remodeling is the major mechanism for day-to-day and minute-to-minute bodily flux of calcium. Osteocytes and bone lining cells, under stimulntion by PTH and other effectors, play u much larger role in determining serum calcium concemrations than the rate ofBTO, both in health and disease (41 for African Americans for low, normal, and high BTO, respectively. Thus, in more current studies in stage 5 CKDMBDs, the presenc;e of low bone volume with low BTO (i.e., ABD) is more frequent than previously appreciated, and defects of mineralization (i.e., osteomalacia and aluminum deposition) are rare. This study also confirmed that differences in CKD-MBDs exist within and between races, and treatment guidelines may therefore not apply similarly to all patients. The NKF 2002 KDOQI (2) and 2009 KDIGO (9) guidelines accept a wide range of elevated PTH levels (2 to 9 times the upper limit of normal) as being optimal in late-stage CKD. In 2008, Barreto and colleagues (65) compared bone histomorphometry at baseline and 1 year in 97 patients with stage 5 CKD requiring hemodialysis in order to assess the recqmmended KDOQI PTH range of between 150 and 300 pg/mL. They found that intact PTH levels <150 pg/mL for identifying low BTO and >300 pg/ mL for idcntif-fing high DTO had positive predictlv~ vaiues of83 and ~2?1' , respectively.
Vascular or Soft Tissue Calcification in CKD-MBDs
· The risk of any cardiovascular event (6), cardiova~cu-lar death ( 66), and death from any cause ( 6 ,66 ,67) increases sharply as the eGFR declines below 60 mL/min ( Fig. l and  3) . In a prospective cohort.study of 382 patients with stage 3 to 5 CKD, the annual mortality rates for stages 3, 4, and 5 were 3.9, 6.3, and 9.2%, respectively (67). However, traditional CVD risk facto.rs do not entirely account for the elevated mortality in CKD, as seen in a prospective srudy of 3,879 patients with stage 2 to 4 CKD followed for a median of 3 .5 years (29) .
Hyperphosphatemia, an elevated calcium-phosphate product (Ca x P) (68) , and SHPT have all been linked to increased arterial vascular calcification and/or CVD mortality. As CKD-MBDs progress, there is a physiologic change for vascular tissue to acquire bone cell characteristics, with a secondary deposition of calcium in arterial (44) assessed BMD and aortic calcification via lumbar computed tomography (CT) and found osteoporosis in 70% of subjects, with the degree of aorti~ calcium accumulation inversely related to skeletal BMD and directly related to fracture. This is in keeping with earlier (electronic beam) coronary CT findings of an association between the degree of coronary calcification and bone loss (69) . Arterial vascular calcification begins as early as stage 3 CKD and is strongly linked to bone loss, CVD, and increased mortality. SHPT is associated with bone loss in patients with CKD (19) , and low BMD is a risk factor for mortality in patients with ESRD needing dialysis (68) . Low BTO in CKD may also accel. erate CVD if circulating calcium and/or phosphorus exceed skeletal requirements and an elevated Ca x P e)lsues' (vascular calcification may be accelerated if the tissue Ca x P exceeds 55).
Assessment and Diagnosis in CKD-MBDs
Renal Function, Minerals, and Horrnones
An assessment of renal function by measurement of serum creatinine and calculation of the eGFR (http://www. • (40), and osteoporosis may be diagnosed if the DXA BMD T-score is s -2.5 or if the patient has had a prior spine or hip fragility fracture (78 ,79) . Because men and women .~ith stage 4 CKD (GFR, 15 to 29 mL/min) or worse are often >60 to 70 years of age. (Table 5) , and botjl age and renal failure are strong risk factors for fracture, consideration of BMD measurement also seems warranted in'these patients. However, anterior-posterior lumbar spine DXA may be falsely elevated if aortic calcification is present, as it cannot 'be excluded from the anteriorsposterior DXA measurement. Lateral DXA imaging may be useful in CKD, as it was significantly correlated with CT in identifying vascular calcification and measuring BMD in a study of 44 men and women with stage 3 to 4 CKD (80). It is import&nt to_consider thoracic and lumbar spine radiographs or a vertebral fracture assessment at the time of BMD measurement (especially in patients with significant loss of height, back pain, or ESRD) to assess for not only prior vertebral fractures but also arterial vascular calcification, both of which increase fracture risk and may demand more aggressive therapy for CKD-MBDs (81). Neither DXA BMD nor volumetric quantitative CT (vQCT) can identify the underlying bone pathology in CKD-MBDs (e.g., SHPT, osteitis fibrosa,ABD, and osteomalacia). The DXA technique also cannot differentiate cancellous from cortical bone in the spine or elsewhere, although this !_imitation does not apply to vQCT sc_ans, and vQCT of cortical lumbar bone has been shown to be predictive of vertebral fracture risk in ESRD (82). Rix et al (19) i~entified the hip and radius as important locations of bone · loss in patients with elevated PTH values and a GFR of 20 to 80 mL/m.in (stage 2 to 4 CKD), corroborating earlier reports of the catabolic effects of SHPT on cortical bone.
The importance of cortical bone loss in CKD is magnifi~d by concerns regarding its irreversibility and high rates of hip fracture documented in dialysis patients (47). Malluche · et al (22) reviewed 630 iliac crest biopsies in patients with ESRD and found that three-quarters of African Americans had normal cortical thickness but high porosity, whereas there was approximately the same number of Caucasians who had low or normal cortical thickness and normal or high porosity. Cortical bone has a lower BTO rate than cancellous bone and provides a rigid outer shell to long bones ihat serves primarily as a structural barrier to fracture. Caricellous bone consists of an internal trabecular meshwork that provides flexibility and strength to the bone and also provides a greater surface area that undergoes more r~pid BTO and bone remodeling than cortical bone. The differences between bone loss in cortical and cancellous bone, as well as differenc~s in BTO in each of these skeletal compartments, may indeed have important clinical implications as to f!acture risk. . .
Hip fractures are a significant complication in stage 5 CKD-MBDs (46, 47, 83) , with a reported incidence up to 17 times greater than seeo in the general population (83) . In a retrospective study of 9,007 dialysis patients; a_ U-curve relationship between fracture risk and PTH level was detected, with fracture risk comparable at all skeletal sites_ for lowest and highest PTH levels (84). Of interest, in dialysis patients with SHPT, following PTX tht?re is a significant decline in FGF-23 and the Ca x P (36), a reported 32 and 31 % decreased fracture rate for ·mp and any skeletal fracture, ,respectively (85), and 10 to 15% lower long-term mortality (24) . _Among patients with ESRD requiring hemodialysis, · a meta-analysis of 683 patients found that lower DXA BMD measurements are related to increased fracture risk ( 46). However, in 52 men and women also with ESRD needing dialysis and followed for 1 year, high-resolution peripheral quantitative CT scannihg of the radius was found to be predictive of nonspine fractures, whereas neither hip nor spine DXA BMD accurately predicted fractures (86) . One possible .explanation for these findings is that ESRD patients have a selective declii:ie in cortical (versus trabecular) bone that may not be identified by DXA.
Biochemical Markers ( BCM) and Bone Biopsy
In patients with stage 3 to 5 CKD, KDIGO guidelines recommend baseline measurement of serum PTH and BAP and suggest not to routinely measure bone-derived BCMs of collagen degradation (Le., type I collagen cross-linked telopeptides C-TX and N-TX, pyridinoHne, and deoxypyridinoline). BAPis probably the best readily available BCM for assessing bone fonnation in CKD, as it is not excreted by the kidney !IJld increased levels virtually exclude the presence of ABD (57) . Although BAP eleva~on in CKD likely reflects SHPT, it may also signify recent fracture, hypovitaminosis D, osteomalacia, or (rarely) other metabolic bone disorders. A significantly elevated PTH also excludes ABD, and marked PTH elevation (6 times above normal) is indicative of osteitis fibrosa. Normal BAP and nonnal to slightly elevated PTH levels in Jate CKD need to be viewed with caution for possible ABD. · · The _'gold standard' for the _diagnosis and c~assi.fication of CKD-~BDs is the tetracycline double-labeled bone biop_sy. A bone biopsy requires the. patient to be referred to a trained physician-surgeon and medical center that can obtain a proper 'core' iliac crest biopsy for histomorphometric analysis, the latter done at only a few center.sin the U.S. In situations where it is not clear wh~ther high or low BTO disease or osteomalacia is present, particularly in latestage CKD with normal lo mildly elevated PTH, an iliac Ciest bone biopsy can help distinguish between types of CKD-MBDs (Table 3 and Fig. 2) (38) . Bone biopsy studies have shown an increased prevalence of low BTO during stage 5 CKD in Caucasians, with high BTO common in African Americans (22) . The pre:valence of CKD-MBDs has increased in. the p~st few decades with an increase in both SHPT-related osteitis fibrosa and ABD (57) . The cause of this tral)sition is not yet clear.
Treatment of CKD-MBDs
The development of treatment options that can safely and effectively add.ress 'serum phosphorus, PTH levels, bone-density, CVD, and mortality in patients with CKDMBDs continues to evolve (57 ,87) .
Calcium
Calcium supplementation· in late-stage CKD, particularly when ABD may be present, remains controversial because it may not improve BMD (88) and may accelerate vascular calcification and CVD risk by increasing the Ca
x P. The NKF KDOQI ;md KDIGO guidelines do not give specific recommendations for calcium supplementation in stage 4 to 5 CKD. Calciwn can serve as a phosphate binder, although the trend has been away from calcium use in late CKD-MBDs due to other effective phosphorus binders and concern over raising the Ca x P. In a small study of 19 patients with stage 3 to 4 CKD who consumed a lowphosphate diet, administration of calcium acetate lowered elevated serum PTH levels and urinary phosphate excretion without changing serum calcium or phosphate levels (35) . A larger study of 1,188 men (24% African American) having predominately stage 2 to 4 CKD (8% sf-age 2, 57% stage 3, 30% 11tage 4) reported lower mo~ality over 3 years when using a calcium phosphate binder (median calcium dose 7_ 80 mg/day; 507 to 1,014 mg/day at the 25th to 75th · percentiles) (89). Spiegel and Brady (90) performed calcium balance studies using 800 mg versus 2,000 mg calcium diets in healthy individuals and patients with stage 3 to 4 CK.D. After 9 days, negative calcium balance occuned in both groups eating an 800-mg calcium diet, whereas the 2 ,000-mg diet resulted in posWve calcium balance that was lliud~l in h~thy persons and marked in those with (;KU. The higher-calcium diet significantly decreased PTH and 1,25-dihydroxyvitamin D levels without changing the serum calcium concentration. Thus, in early CKD, ensuring a modest (1,000 to 1,200 mg) calcium intake· appears to be safe and reasonable. In late CKD, some advocate using 200 mg of calcium at each ~eal as a phosphate binder before the use of other phosphate-binding agents (91) . Others suggest prescribing calcium with caution in iate CKD, as randomized controlled trials (RCTs) in patients with ESRD have shown progression of vascular calcification (92) . Whether or not calcium supplementation in ESRD leads to increased CVD events has not been well studied.
Phosphate Binders
Dietary phosphate restriction and the use of phosphate binders are helpful in the treatment of hyperphosphatemia and SHPT with secondary lowering of FOF-23 (34, 35, 89, 91) . Lowering serum phosphorus also increases production of calcitriol, whic4 has _a-direct effect on the parathyroid glands to decrease PTH production and secretion. Sevelamer carbonate and lanthanum carbonate are effe~tive noncalcium phosphate binders but have been traditionally used after hyperphosphatemia occurs in stage 4 to 5 CKD. Sevelamer and calcium acetate progressively lowered urine phosphate and serum PTH in 40 patients with stage 3 CKD ( creatinine clearance, 34 .5 mUmin) and SHPT. Importantly, FGF-23 levels were significantly lo~-ered only by sevelamer, an effect not mediated by (nonsignificapt) changes in serum phosphorus or 1,25-dihydroxyvitamin D (35) . The addition of lanthanum to a low-phosphate diet in 18 patients with stage 3 CKD significantly lowered urine phosphorus excretion, tubular reabsorption of phosphorus, and serum FGF-23 levels without changing serum phosphorus or PTH levels (34) . Although short-and lon· g-term studies of the use of phosphate bind-· ers in stage 3 CKD-MBDs appear promising, long-tenn prospective clinical trjals will be needed to detem:i.ine if earlier use of phosphate binders will delay development of late~stage CKD-MBDs and reduce mortality (91) ,
VitaminD
Hypovitaminosis D is common in both_ the general population (49, 50) VD Ra Analogs · FGF-23 elevation may inhibit PTH mRNA activity, osteoblast differentiation, and bone matrix maturation. Thus, FGF-23 elevation may result in delayed increase in PTH concentrations (anq. therefore delayed therapy) and suppressed BTO as early as stage 2 to 3 CKD : VDRa analog therapy is expected to mitigate bone loss in CKDMBDs by both suppre~sing PTH-stimulated bone resorption and by preventing low BTO · due to its stimulatory effect on nonnal osteoblast differentiation (94) . There may _ also be dfrect effects that inhibit osteoclastogenesis (47-) . Presently, the indication for VDRa analogs in CKD is predicated on lowering elevated serum phosphate and/ or PTH levels. However, th~ administration of VDRa analogs in early CKD-IvIBDs with SHPT is often avoided because of concern that oversuppression of PTH ,viU promote low BTO and development of ABD, as can be seen in late CKD-MBDs (57, 59) . In addition, there may be c~m-cems of adverse effects to include an elevated Ca x P that may accelerate CKD progression. However, in one study, low-dose calcitriol use in stage 5 CKD patients resulted in rna_t'kedly less PTH rise th.an in controls and significant improvement in both spine and hip BMD (76) .
RCTs have assessed the use of the VDRa analogs alfacalcidol (23, 70) , paricalcitol (95 ,96) , calcitriol (96) , and doxercalciferol (97) ID stage 3 to 4 CKD-MBDs compared with placebo. Alfacalcidol reduced high PTH levels and prevented bone loss at the spine and hip in patients with a GFR of 20 to 60 mLJmin (stage 3 to 4 CKD) (70) . This is consistent with an earlier bone histomorphometric study in patients with a GFR. of 15 to 50 mL/min that showed alfacalcidol reduced high BTO to more normal values, did not cause abnormally low BTO or ABD, and improved bone formation in the setting of pretreatment ABD (23) . Paricalcitol treatment also significantly reduced elevated .PTH levels in stage 3 to 4 CKD in 220 patients over. 24 weeks (average PTH declined by 42%, with 30% suppression in 90% of patients) (95) and in 263 patients over 32 weeks (>50% PTH reduction in 62% of patients) (96) . In this latter RCT, compared with placebo, calcitriol significantly reduced PTH levels (by :::-50%) in 54% of patients. In these RCTs, serum calcium levels increased for patients ta1cing calcitriol and alfacaleidoJ, but neither paricalcito.I nor doxercalcif erol were different from controls as to hypercalcemia, hyperphosphatemia, Ca x P, 4ypercalci-uria, or adverse eve~ts. ·
Drugs to Treat Osteoporosis
Approved therapies for osteoporosis in the U.S. include antiresorptive agents that reduce BTO and an anabolic agent that stimulates bone fonnation. In postmenopausal women with osteoporosis, bisphosphonates inhibit .osteoclast-mediated bone resorption and ~ecrease rates of BTO to premenopausal levels. Titis is usually .associated with an increase in BMD, more at cancellous than cortical bone sites. Bisphosphonates are ~xcreted by the kidney, and· the U.S. Food and Drug Administration (FDA) approved labeling for cUITently available bisphosphonates indicates that these agents should not be used to· treat osteoporosis in patients with significantly impaired renal function (GFR <35 mL/min for alendronate and zoledionate and <30 mL/min for risedronate and ibandronate). Retrospective reviews and secondary analyses of previously published RCTs with the antiresorptive drugs risedronate (71), alen-. dronate (72) , raloxifene (73) , and denosuniab (75) have reported both inqeased BMD and reduced fracture incidence without worsening renal function in pafamts with early CKD (few patients had an eGFR <30 mL/min in any of these studies). Because bisphosphonates may increase the risk of low BTO and ABD as CKD progresses, they are generally not recommended for the treatment of bone loss in late (stage 4 to 5) CKD. Denosumab is a human monoclonal antibody to the RANKL. Denosumab blocks !}le binding of RANKL to RANK and thereby decreases the number and activity of osteoclasts, decreases bone resorption and BTO, increases BMD, and significantly decreases spine and hip fractures in postmenopausal women (98 The biological action of PTH on bone largely depends on pulsatile PTH secretion. This may explain the risk for ABD in patients receiving active vitamin D via suppression of PTII release, whereas dialysis patients have a constant exposure to high calcium dialysate levels, which can also suppress PTH. Teriparatide is a human ·recombinant honnone that. contains the initial amino acid sequence (residues 1 through 34) of the complete 84-amino acid sequence of naturally oqcurring human PTH. However, the use of cinacalcet in stage 3 to~ CKD has yet to be approved and remains controversial. Only one RCT 0f cinacalcet use in stage 3 to 4 CK.D has been published (103) . In that 32 week study of 404 patients, cinacalcet was found to significantly reduce elevated PTH levels compared with controls (43% versus 1 %). In addition, semm calcium levels were significantly lower (8.9 mg/d.L versus 9.9 mg/dL), and serum phosphorus levels trended higher (4.5 mg/dL versus 4.0 mg/dL) with cinacalcet use, but no adverse mineral or renal events were noted. Because cinacnlcet may-increase the risk of hypocalcemia, it'is presently generally reserved for patient use in stage 5 CKD, although it has been safely administered in patients with stage 3 to 4 CKD who were not candidates for PTX (104) . Initiating cinacalcet at low dose with gradual titration upward as needed may reduce the risk of hypocalcemia.
DISCUSSION
The focus of this article ii, lu bdcfly review the patho-. physiology of CKD-MBDs ~d to call for increased awareness of the NKF KDIGO guidelines and the early features of CKD-MBDs that can be evaluated and treated. In addition, this review discusses differentiating CKD-MBDs from tradi'tiooal clinical criteria for assessment and treatment of osteoporosis. Early (stag~ 1 to 3) CK.D comprises the majority (96%) of patients with CKD in the U.S. Treatment of CKD-MBDs is complicated by progressive changes in serumFGF-23, calcium, phosphate, PTH, and 1,25-dihydroxyvitamin D levels, with-changes in bone mass and histology as kidney function declines. Management of bone loss !lSSociated with stage 2 to 4 CKD-MBDs is possible with judicious selection of calcium, vitamin D and VDRa analogs, antiresorptive agents (bispho~phonates or denostimilb), or teriparatide anabolic therapy. In situations where the type of bone disease is not clinically evident and treatment choice is unclear, a tetracycline--labeled iliac crest bone biopsy can be used to help determine'the presence of high or low BTO or osteomalacia. The limitation of all of the above--noted studies with bisphosphonates, denosumab, teriparatide, and cinacalcet is that effects of treatment on vascular calcification, bone histomorphometry findings, and other clinical outcomes were not all included in the various study designs.
CONCLUSION
Almost 40% of the U.S . population <1:60 years old have CKD, a population age group already dealing with a high prevalence of obesity, T2DM, dyslipidemia, HTN, and age-rdated bone loss. These diseases impact thP. progression of CKD-MBDs and vice versa. The close association of renal failure with vascular calcification, CVD, and increased mortality mandates earlier recognition and treatment of CKD-MBDs. The endocrinologist is uniquely positioned to address and treat not only early CKD-MBDs but also many of the metabolic and skeletal disorders that accompany CKD-MBDs.
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